BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...

Doxycycline is one of the strongest photosensitizers, and phototoxicity is reportedly linked to lumidoxycycline, [2] one of its photoproducts. The pathogenesis of drug-related nail disorders is ...

The FDA has approved Attruby, a new oral treatment that helps reduce heart-related deaths and hospital visits among adults ...

The stock market responded positively to the company's announcement, with its share price leaping more than 28% following the ...

The first drugs against Alzheimer's disease that are intended to slow down the progression of the condition will soon be authorized in Germany. On November 14, 2024, the EMA granted approval for ...

Drug discovery researchers have found that a natural fat molecule called 'lipoxin A4' (LXA4) could significantly reduce inflammation and improve function for diabetic hearts. The preclinical study ...

A new type of therapy that 'edits' a gene in patients with a rare heart condition has been shown to be safe and effective, according to research from UCL and the Royal Free Hospital.

1979) (see Table 1). A 100 mg dose taken twice daily of either minocycline or doxycycline is also effective. Full-strength dosing should last for 3–4 weeks or until a response is noted ...

The ability of the human heart to renew itself by regenerating its muscle cells, myocytes, is very limited. But what happens to this capability when the heart is damaged by severe heart failure ...

The Food and Drug Administration (FDA) has approved Attruby TM (acoramidis) for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to ...

A potentially life-changing heart condition, dilated cardiomyopathy, can be caused by the cumulative influence of hundreds or thousands of genes and not just by a single "aberrant" genetic variant, as ...

Ultromics Ltd. received clearance from the U.S. FDA for Echogo Amyloidosis, its artificial intelligence-enhanced software ...